Hidrops fetal por infección congénita por citomegalovirus: tratamiento posneonatal prolongado con valganciclovir

cytomegalovirus (cmv) is the leading cause of congenital infection affecting 0.5% of all live births. primary cmv infection occurs in 1-4% of seronegative woman during pregnancy and may be transmitted to the fetus in 40%. up to 10% of intrauterine cmv infections result in symptomatic congenital disease at birth. we present a case of congenital cmv infection in the third trimester of gestation with central nervous disease involvement, who was treated with intravenosus ganciclovir followed by oral valganciclovir for six months with successful results in the first year of life. we review the literature on the diagnosis and prognosis of newborns with congenital cmv infection and the expectations and current experience of treatment with ganciclovir and valganciclovir.